Is Zynerba Pharmaceuticals Inc (ZYNE) a Good Buy in the Healthcare Sector?

Monday, November 29, 2021 03:44 PM | InvestorsObserver Analysts

Mentioned in this article

Is Zynerba Pharmaceuticals Inc (ZYNE) a Good Buy in the Healthcare Sector?

Zynerba Pharmaceuticals Inc (ZYNE) is around the top of the Healthcare sector according to InvestorsObserver. ZYNE received an overall rating of 31, which means that it scores higher than 31% of stocks. Additionally, Zynerba Pharmaceuticals Inc scored a 76 in the Healthcare sector, ranking it higher than 76% of stocks in that sector.

ZYNE has an Overall Score of 31. Find out what this means to you and get the rest of the rankings on ZYNE!

See Full ZYNE Report

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. *Investors Observer* allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 31 would rank higher than 31 percent of all stocks. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in the healthcare sector with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Zynerba Pharmaceuticals Inc Stock Today?

Zynerba Pharmaceuticals Inc (ZYNE) stock is lower by -2.22% while the S&P 500 has risen 1.5% as of 3:44 PM on Monday, Nov 29. ZYNE has fallen -$0.08 from the previous closing price of $3.60 on volume of 1,679,867 shares. Over the past year the S&P 500 has gained 28.77% while ZYNE has fallen -24.14%. ZYNE lost -$1.04 per share the over the last 12 months. Click Here to get the full Stock Report for Zynerba Pharmaceuticals Inc stock.